Critical Survey: Senomyx (SNMX) versus Its Peers

Senomyx (NASDAQ: SNMX) is one of 198 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Senomyx to similar businesses based on the strength of its earnings, analyst recommendations, institutional ownership, valuation, risk, dividends and profitability.

Risk and Volatility

Senomyx has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Senomyx’s competitors have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.

Earnings & Valuation

This table compares Senomyx and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Senomyx $19.56 million -$11.72 million -3.46
Senomyx Competitors $207.79 million -$2.30 million 0.50

Senomyx’s competitors have higher revenue and earnings than Senomyx. Senomyx is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Senomyx and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Senomyx -63.38% -85.22% -54.58%
Senomyx Competitors -3,963.69% -118.21% -43.73%

Institutional and Insider Ownership

28.9% of Senomyx shares are owned by institutional investors. Comparatively, 46.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 12.4% of Senomyx shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Senomyx and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senomyx 0 3 0 0 2.00
Senomyx Competitors 481 2270 6200 119 2.66

Senomyx presently has a consensus price target of $2.00, suggesting a potential upside of 122.22%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.15%. Given Senomyx’s higher possible upside, equities analysts plainly believe Senomyx is more favorable than its competitors.


Senomyx competitors beat Senomyx on 9 of the 12 factors compared.

Senomyx Company Profile

Senomyx, Inc. is focused on using taste receptor technologies to discover, develop and commercialize flavor ingredients for the packaged food, beverage and ingredient supply industries. The Company operates through development and commercialization of flavor ingredients segment. It is engaged in the discovery, development and/or commercialization of flavor ingredients through over five programs. The Sweet Taste Program is focused on developing flavor ingredients or discovering natural sweeteners. The Savory Flavor Program is focused at flavor ingredients to be used in product categories, such as ready meals, sauces, soups and snack foods. The Bitter Blocker Program is focused on flavor ingredients used in products that contain bitter tastants. The Cooling Taste Program is focused at flavor ingredients used in products that consist of cooling agents. The salt taste modifier program is focused on reduction of the level of salt contained in packaged food and beverage products.

Receive News & Ratings for Senomyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senomyx Inc. and related companies with's FREE daily email newsletter.

Leave a Reply